India is likely to get 97.1 million doses of AstraZeneca vaccine against Covid-19 under an agreement with the WHO COVAX facility, as this forecast has been mentioned at COVAX’s interim distribution forecast, which was published on 3’rd February 2021.
The fraction to be made available to India will be manufactured and supplied by the Pune’s Serum Institute of India, which India has already received for the initial phase of vaccination that began in the country from 16’th January 2021. India has so far inoculated around more than 4 million healthcare workers either with Covishield or Covaxin.
The vaccine doses will be in addition to India’s direct deal with Pune’s SII (Serum Institute of India) as this is being done by Covax facility, which will also cover several other nations. Data suggests that Brazil will be getting 10.6 million doses, Bangladesh 12.8 million, Indonesia 13.7 million, Nigeria 16 million, and Pakistan 17.2 million.
The Covid-19 Vaccines Global Access Facility was set up to counter vaccine nationalism, keeping in mind the condition of the poorer nations which might be left behind in the global vaccine race. It is backed by the Vaccine Alliance, Gavi, WHO and the Coalition for the Epidemic Preparedness Innovations. Covax is going to distribute the Oxford COVID-19 vaccine and Pfizer-BioNTech COVID-19 vaccine but India will get the Oxford COVID-19 vaccine from the facility.
On behalf of its data, it will distribute 240 million doses of Oxford-AstraZeneca COVID-19 vaccine, licensed to Serum Institute, 96 million doses of Astrazeneca-Oxford vaccine, under an agreement between Gavi and Astrazeneca and 1.2 million doses of Pfizer COVID-19 vaccine.